ATARA Biotherapeutics (ATRA) Prices 5.102M Share Common Offering at $24.50/Sh

Citi Downgrades Atara Biotherapeutics (ATRA) to Neutral

Citi analyst Yigal Nochomovitz downgraded Atara Biotherapeutics (NASDAQ: ATRA) from Buy to Neutral with a price target of $27.00 (from $20.00).

For an analyst ratings summary and ratings history on Atara Biotherapeutics click here. For more ratings news on Atara Biotherapeutics click here.

Shares of Atara Biotherapeutics closed at $25.82 yesterday.

Pre-Open Stock Movers 12/08: (LXRX) (SFIX) (SMAR) Higher; (PEN) (CONN) (MRNS) Lower (more...)

Pre-Open Stock Movers

Lexicon Pharmaceuticals (NASDAQ: LXRX) 38% HIGHER; Citi upgraded from Neutral to Buy with a price target of $6.00 (from $2.10).

Stitch Fix (NASDAQ: SFIX) 37.9% HIGHER; reported Q1 EPS of $0.09, $0.29 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $490.4 million versus the consensus estimate of $481.17 million. Also announced that... More

After-Hours Stock Movers 12/07: (SFIX) (HOLI) (SMAR) Higher; (MRNS) (IBIO) (ARCT) Lower (more...)

After-Hours Stock Movers

Stitch Fix (NASDAQ: SFIX) 37.9% HIGHER; reported Q1 EPS of $0.09, $0.29 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $490.4 million versus the consensus estimate of $481.17 million. Also announced that Dan Jedda has joined the company, reporting to Katrina Lake. Jedda will be appointed CFO effective December 9, 2020. Dan Jedda joins the company from Amazon where he was Vice President and CFO for Digital Video (including Amazon Studios), Digital Music, and the Advertising and Corporate Development organizations.

Hollysys Automation (NASDAQ:... More

ATARA Biotherapeutics (ATRA) to Offer $150M of Common Stock

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public... More

Atara Biotherapeutics (ATRA) PT Raised to $33 at Stifel, Following Collaboration Deal Announcement

Stifel analyst Benjamin J. Burnett raised the price target on Atara Biotherapeutics (NASDAQ: ATRA) to $33.00 (from $28.00) while maintaining a Buy rating.

Pre-Open Stock Movers 12/07: (KODK) (CKH) Higher; (RIDE) (XPEV) (JKS) Lower (more...)

Today's Pre-Open Stock Movers

Eastman Kodak Company (NYSE: KODK) 72% HIGHER; news that federal regulators found no wrongdoing in getting a loan from the government.

Kura Oncology, Inc. (Nasdaq: KURA) 16.9% HIGHER; announced preliminary clinical data from KOMET-001, an ongoing Phase 1/2A clinical trial of the Companys oral, potent and selective menin inhibitor, KO-539, including single-agent activity in genetically defined subgroups of patients with relapsed or refractory acute myeloid leukemia (AML).

Matinas BioPharma Holdings, Inc. (NYSE:... More

Bayer and Atara Biotherapeutics (ATRA) Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors

Bayer and Atara Biotherapeutics, Inc. (Nasdaq: ATRA) today announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors. The agreement includes the development candidate ATA3271, an armored allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors such as malignant pleural mesothelioma and non-small-cell lung cancer.

Atara is a pioneer in allogeneic T-cell immunotherapy with industry-leading allogeneic cell manufacturing processes and CAR T technologies. The licensed technology leverages Atara's novel, proprietary Epstein-Barr Virus (EBV) T-cell platform combined... More